First targeted treatment to reduce the risk of ALK positive lung cancer returning after complete tumour removal recommended ...

The draft updated guidance on assessing and preventing falls in older people and people aged 50 and over at higher risk opens ...

Belzutifan (Welireg, Merck Sharp & Dohme) is indicated for 'the treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for VHL associated renal cell carcinoma (RCC), ...

You should read both the consultation document and the accompanying evidence (see the committee papers) before making any comments. You must make your comments ...

The 4 technology appraisal committees are standing advisory committees of NICE. This topic was considered by committee B. Committee members are asked to declare any interests in the technology being ...

When NICE recommends a treatment as an option for use with managed access, NHS England will make it available according to the conditions in the managed access agreement. This means that, if a patient ...

Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...

Belzutifan (Welireg) is available during the managed access period. It is a possible treatment for tumours associated with von Hippel-Lindau (VHL) disease in adults when localised procedures such as ...